Alfredo
Adán Civera
Publicaciones en las que colabora con Alfredo Adán Civera (9)
2024
-
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials
Ophthalmology, Vol. 131, Núm. 6, pp. 708-723
-
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2
Ophthalmology, Vol. 131, Núm. 8, pp. 914-926
2023
-
Effectiveness and safety of fluocinolone acetonide intravitreal implant in diabetic macular edema patients considered insufficiently responsive to available therapies (REACT): a prospective, non-randomized, and multicenter study
International Ophthalmology, Vol. 43, Núm. 12, pp. 4639-4649
2022
-
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
The Lancet, Vol. 399, Núm. 10326, pp. 729-740
-
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
The Lancet, Vol. 399, Núm. 10326, pp. 741-755
2021
-
Challenges in diabetic macular edema management: An expert consensus report
Clinical Ophthalmology, Vol. 15, pp. 3183-3195
2020
-
Use of intravitreal dexamethasone implants in the treatment of diabetic macular edema: Expert recommendations using a Delphi approach
European Journal of Ophthalmology, Vol. 30, Núm. 5, pp. 1042-1052
2018
-
Novel association of high C-reactive protein levels and A69S at risk alleles in wet age-related macular degeneration women
Frontiers in Immunology, Vol. 9, Núm. AUG
2015
-
Role of Systemic Anti-Tumor Necrosis Factor Alpha Treatment in the Reduction of Proliferative Vitreoretinopathy
Journal of Clinical & Experimental Ophthalmology, Vol. 06, Núm. 04